Trajenta · DIN 02370921 · 5 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Trajenta · DIN 02370921
Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-09-28
Health Canada: Marketed since 2011-09-13 · brand TRAJENTA · ATC A10BH05 LINAGLIPTIN · form Tablet · route Oral · ingredients LINAGLIPTIN 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Trajenta: Formulary list price $2.81 per unit (the source does not state the unit; exact figure $2.8120). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370921)
Source record
DIN 02370921: Trajenta
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002041; group id 748; item number 1831; lccId None; manufacturer id BOE
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $2.8120; ministry $2.8120
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370921
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85612
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.
Shortage status: not checked (no credentials)